We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Derived Exosomal Protein Biomarkers in Alzheimer’s Disease Diagnosis

By LabMedica International staff writers
Posted on 04 Aug 2016
Alzheimer’s disease results in brain neuronal plaques composed of amyloid beta peptide (Aβ42) and neurofibrillary tangles composed of phosphorylated tau proteins (P-T181-tau and P-S396-tau). More...
Exosomes are shed by brain neurons, freely cross the blood brain barrier and protect and carry proteins from their cellular origin into plasma.

P-T181-tau and P-S396-tau are present at higher than normal concentrations and Aβ42 at lower than normal concentrations in the cerebrospinal fluid of Alzheimer’s disease (AD) patients. These proteins are not high in plasma samples of AD patients in part due to poor blood brain barrier transport and protease activities.

Scientists at Pan Laboratories (Irvine, CA, USA) and their colleagues validated enzyme-linked immunosorbent assays (ELISA) for Aβ42, P-T181-tau and P-S396-tau, and used them to quantify these proteins in neuron-derived exosomal extracts from normal and AD plasma samples. Plasma samples were obtained from patients with mild cognitive impairment (MCI) and dementia due to Alzheimer’s disease (AD), as well as matched normal controls. Exosomes were precipitated from the plasma samples using the ExoQuick preparation (System Biosciences, Palo Alto, CA, USA).

The team reported that ELISA assays for Aβ42, P-T181-tau and P-S396-tau were reproducible and the Inter-assay Coefficient of Variability (CV) was less than 15%. The sensitivity of the biomarker ELISAs varied from 2 to10 pg/mL. Neuron-specific exosomes were prepared from the plasma of normal controls, MCI and AD patients. The reproducibility of the exosome preparations and biomarker levels were monitored in each ELISA. All biomarkers were elevated in MCI patients and AD patients compared to normal.

The authors concluded that they have validated a reproducible procedure to isolate specific neuron-derived exosomes for quantification of specific protein biomarkers in plasma samples. The concentrations of the biomarkers are high in patients with early dementia and Alzheimer’s disease. This procedure may be useful in the early diagnosis of Alzheimer’s disease. The study was presented at the 68th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting held July 31 to August 4, 2016, in Philadelphia, PA, USA.

Related Links:
Pan Laboratories
System Biosciences
American Association of Clinical Chemistry

Gold Member
Hybrid Pipette
SWITCH
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
ESR Analyzer
TEST1 2.0
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: Development of targeted therapeutics and diagnostics for extrapulmonary tuberculosis at University Hospital Cologne (Photo courtesy of Michael Wodak/Uniklinik Köln)

Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis

Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. Despite TB infecting 10 million people yearly, the... Read more

Pathology

view channel
Image: The AI tool combines patient data and images to detect melanoma (Photo courtesy of Professor Gwangill Jeon/Incheon National University)

AI Tool to Transform Skin Cancer Detection with Near-Perfect Accuracy

Melanoma continues to be one of the most difficult skin cancers to diagnose because it often resembles harmless moles or benign lesions. Traditional AI tools depend heavily on dermoscopic images alone,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.